A Look At Bavarian Nordic (CPSE:BAVA) Valuation After Recent Mixed Share Price Performance

Simply Wall St

Mon, February 16, 2026 at 2:06 PM GMT+9 3 min read

In this article:

BVNKF

-1.83%

BVNRY

-0.10%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Bavarian Nordic (CPSE:BAVA) has drawn investor attention after recent share price moves, with a 0.6% decline on the day and mixed returns across the past week, month, and past 3 months.

See our latest analysis for Bavarian Nordic.

At the current share price of DKK192.0, Bavarian Nordic’s recent 90 day share price return of 5.49% contrasts with a weaker year to date share price return and a 9.78% one year total shareholder return. This suggests momentum has been patchy as investors reassess growth prospects and risk.

If Bavarian Nordic’s mixed performance has you looking wider in healthcare, this could be a good moment to scan 107 healthcare AI stocks for other vaccine and biotech related ideas.

With Bavarian Nordic trading at DKK192.0, alongside mixed recent returns and an indicated gap to analyst and intrinsic values, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 27.5% Undervalued

With Bavarian Nordic last closing at DKK192.0 against a narrative fair value of DKK265, the current setup frames a clear valuation gap for investors to interpret.

The company’s successful acquisition and revitalization of previously underperforming assets (such as rabies and TBE vaccines), coupled with accelerated manufacturing output to meet surging demand, positions Bavarian Nordic for continued earnings resilience and improved gross margins.

Read the complete narrative.

Want to see what sits behind that confidence in earnings resilience? Revenue trends, margin shifts and a richer future P/E multiple are doing the heavy lifting here.

On this widely followed narrative, Bavarian Nordic’s fair value sits at DKK265, with the analysis built on a 5.21% discount rate, softer revenue expectations and a higher future earnings multiple than today’s pricing implies. The core question for you is whether those revenue, margin and valuation assumptions feel reasonable given your own view on vaccine demand, regulatory pressure and the company’s product mix.

Result: Fair Value of DKK265 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are clear watchpoints, including pressure on vaccine pricing and the risk that recent demand for travel and preparedness vaccines cools faster than expected.

Find out about the key risks to this Bavarian Nordic narrative.

Build Your Own Bavarian Nordic Narrative

If you see the numbers differently or prefer to test your own assumptions, you can create a custom Bavarian Nordic view in just a few minutes, Do it your way.

繼續閱讀  

A great starting point for your Bavarian Nordic research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Bavarian Nordic is only one piece of your watchlist, use the Simply Wall St screener to uncover fresh opportunities that fit your style before others move first.

Target potential mispricings by scanning our list of 230 high quality undervalued stocks that screen well on quality and valuation filters.

Strengthen your core holdings by reviewing a solid balance sheet and fundamentals stocks screener (372 results) that can help you focus on financial resilience.

Hunt for future leaders early by checking a screener containing 569 high quality undiscovered gems that many investors may not be watching yet.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include BAVA.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

條款 及 私隱政策

Privacy Dashboard

More Info